Alan Tribe’s PYC Therapeutics gets kidney drug approved for human trials

[Pelican Press 0]

This is the hidden content, please

• Sign In
• or
• Sign Up

Alan Tribe’s PYC Therapeutics gets kidney drug approved for human trials

Alan Tribe-chaired PYC Therapeutics has received regulatory approval to commence human trials for its drug aimed at addressing polycystic kidney disease.

The clinical-stage biotech will now commence a single ascending dose study for its drug PYC-003 in healthy volunteers and patients with polycystic kidney disease.

The study will be conducted across four sites in Australia, with participants aged between 18 and 60.

Polycystic kidney disease is characterised by multiple cysts forming throughout a patient’s kidney that increase in size over time.

The growth of cysts destroys the function of the kidney, eventually leading to end-stage renal failure and the need for organ transplant in the majority of patients by the age of 55.

About 95 per cent of patients with polycystic kidney disease currently have no treatment options available to them.

PYC is also developing drug candidates for two blinding eye disease and Phelan-McDermid syndrome, a severe neurodevelopmental disorder that affects development, speech and behaviour.

The listed company is chaired by Mr Tribe, who is best known as the former owner of Perth and Adelaide’s Ikea franchises before it was sold to the Swedish furniture giant’s parent company in 2017.

Speaking to The West early this year, PYC chief executive Rohan Hockings said he expected the business to be revenue-generating by 2028 and could have US Food and Drug Administration for three of its drugs by 2029.

This is the hidden content, please

• Sign In
• or
• Sign Up

#Alan #Tribes #PYC #Therapeutics #kidney #drug #approved #human #trials

This is the hidden content, please

• Sign In
• or
• Sign Up

This is the hidden content, please

• Sign In
• or
• Sign Up